1. Home
  2. LKFT vs NTLA Comparison

LKFT vs NTLA Comparison

Compare LKFT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakefront Biotherapeutics American Depositary Shares

LKFT

Lakefront Biotherapeutics American Depositary Shares

N/A

Current Price

$28.13

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$10.89

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LKFT
NTLA
Founded
N/A
2014
Country
Belgium
United States
Employees
452
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
LKFT
NTLA
Price
$28.13
$10.89
Analyst Decision
Buy
Analyst Count
0
23
Target Price
N/A
$20.02
AVG Volume (30 Days)
149.8K
4.3M
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.92
52 Week Low
$27.75
$7.95
52 Week High
$30.91
$28.24

Technical Indicators

Market Signals
Indicator
LKFT
NTLA
Relative Strength Index (RSI) 40.05 32.00
Support Level N/A $8.59
Resistance Level $30.25 $15.52
Average True Range (ATR) 0.56 0.80
MACD -0.24 -0.35
Stochastic Oscillator 10.77 10.20

Price Performance

Historical Comparison
LKFT
NTLA

About LKFT Lakefront Biotherapeutics American Depositary Shares

Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: